

# **MEDICAL PRODUCT ALERT**

**DRAP ALERT NO.** Nº I/S/12-24-57

# RECALL NOTICES ISSUED BY PROVINCIAL DRUG TESTING LABORATORIES.

Date: 31st December, 2024.

#### **Target Audience:**

- National Regulatory Field Force of DRAP and Provincial Drug Control Departments.
- Healthcare Professionals (Physicians, Pharmacists & Nurses) & Veterinary professionals.
- General Public.

### **Alert Summary:**

DDCP PV Lahore and Secretary PQCB Quetta has informed DRAP regarding recall of following batches of mentioned products:

| S# | Product Name   | Batch No. | Manufactured by  | Test Results                   |
|----|--|-----------|--|--------------------------------|
| 1  | Injection I-Vitamin Super 100ml (FOR VET USE ONLY) (Each ml contains: sodium Selenite 0.5mg, Vit. E 70mg, Vit. B12 0.1mg, Vit. B1 20mg, Adenosine-5 Monophosphate 5mg) Reg# 062066 | 6501      | International Pharma Labs,<br>Raiwind Road, Bhobtian<br>Chowk, Defence road, 1Km<br>towards Kahna, Lahore. | Adulterated and<br>Substandard |
| 2  | Injection Oxytocin 50ml<br>(FOR VET USE ONLY)<br>(Oxytocin 10IU/ml)<br>Reg# 020830   | OXY-2219  | Lawrance Pharma (Pvt.) Ltd.,<br>10.5 Km Shekhupura road,<br>Lahore.  | Substandard                    |
| 3  | Injection Flagyl 100ml<br>(Metronidazole 500mg/100ml)<br>Reg# 005102   | AD354     | Sanofi-Aventis Pakistan Limited, Plot no. 23, Sector 22, Korangi Industrial Area, Karachi.                 | Substandard                    |
| 4  | Capsule Esopase 20mg<br>(Esomeprazole 20mg)<br>Reg# 045914   | 3K159     | Lucky Core Industries Ltd.,<br>32/2A, Phase 3, Industrial<br>Estate Hattar                                 | Substandard                    |

#### **Action initiated: -**

The regulatory field force of DRAP and Provincial Drug Control departments have been requested to immediately conduct market surveys for detection and removal of these products from the market.

### **Advice for Healthcare Professionals: -**

DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare









facilities likely to be affected by batches of mentioned products. Adverse reactions or quality problems experienced with the use of these products are to be reported to the National Pharmacovigilance Centre (NPC), DRAP using Adverse Event Reporting Form or online through this <u>link</u>. Further information of reporting problems to DRAP is available on this <u>link</u>.

## Advice for Consumers / general public: -

Consumers should stop using products bearing the affected batch number(s) and shall contact to their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product, and report the incident to Drug Regulatory Authority of Pakistan/National Pharmacovigilance Centre.







